Humacyte, Inc. (HUMA)
| Market Cap | 125.09M-73.4% |
| Revenue (ttm) | 2.12M |
| Net Income | -96.67M |
| EPS | -0.51 |
| Shares Out | 277.80M |
| PE Ratio | n/a |
| Forward PE | -1.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 648,368 |
| Open | 0.47 |
| Previous Close | 0.47 |
| Day's Range | 0.45 - 0.48 |
| 52-Week Range | 0.45 - 1.90 |
| Beta | 2.44 |
| Analysts | Buy |
| Price Target | 1.63(+260.87%) |
| Earnings Date | Nov 12, 2026 |
Humacyte, Inc. has a live Insider Score.
Scored on 3 qualifying trades from 1 insider in the last 90 days.
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$HUMA stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of HUMA by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Tommy TubervilleSenate / R | Purchase$1.00K – $15.00K | Mar 21, 2024 |
| Tommy TubervilleSenate / R | Purchase$15.00K – $50.00K | Mar 21, 2024 |
Recently reported changes in HUMA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by HUMA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
HUMA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New HUMA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to HUMA from public contracts
Source: USAspending.gov
HUMA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from HUMA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score